A pilot study conducted on 21 subjects [104] with postprandial hypoglycemia showed that canagliflozin (300 mg/day) significantly reduced blood glucose and insulin levels 60 min after a meal following the intake of 100 g of glucose during an oral glucose tolerance test in patients with previous RYGB. This evidence concerns the gene INS and Hypoglycemia.